文献速递慢病管理预防保健、筛查与疫苗

代谢功能障碍相关脂肪性肝病的诊断与管理

Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.
PubMed 文献 · Am Fam Physician · 2026-01-01

本文综述代谢功能障碍相关脂肪性肝病(MASLD)的定义、风险分层与基层管理。筛查晚期纤维化采用两步序贯无创检测,先用FIB-4指数分层,不确定或高风险者再行振动控制瞬时弹性成像或超声方法评估。基层应管理早期阶段并开展生活方式干预,包括减重、健康饮食与运动。

要点

  • MASLD定义为肝脂肪浸润伴至少一项心血管代谢危险因素,无继发原因且酒精摄入无或低。
  • 筛查晚期纤维化采用两步序贯无创检测,先用FIB-4指数进行风险分层。
  • FIB-4不确定或高风险者需行振动控制瞬时弹性成像或超声方法二次评估。

核心结论

  • MASLD是日益常见的慢性肝病病因,合并糖尿病、肥胖等危险因素者长期不良结局风险更高。
  • 基层管理早期MASLD并开展生活方式干预可能降低不良结局风险并在转诊前优化照护。

研究设计与样本

  • 本文为综述,总结MASLD的定义、风险分层、筛查与基层管理策略。

主要发现

  • MASLD为肝脂肪浸润伴至少一项心血管代谢危险因素、无继发原因且酒精摄入无或低。
  • 合并糖尿病、肥胖等其他危险因素者发生肝硬化与肝细胞癌等长期不良结局的风险更高。

关键数值与推荐

  • 筛查晚期纤维化采用两步序贯无创检测,先用FIB-4指数进行风险分层。
  • FIB-4不确定或高风险者需行振动控制瞬时弹性成像或超声方法二次风险评估。
  • 超重或肥胖者建议至少减重5%以改善脂肪变并降低心血管风险。
  • 建议健康饮食与每周至少150分钟中等强度有氧运动。
  • 建议戒烟;无或轻度纤维化者限制酒精摄入,纤维化更显著者不饮酒。

临床怎么用

  • 基层医生可用FIB-4指数对MASLD患者进行初始风险分层。
  • FIB-4不确定或高风险者应转介行振动控制瞬时弹性成像或超声方法评估。
  • 在基层开展生活方式干预并管理MASLD早期阶段,在专科转诊前优化照护。

局限性

  • 本文为综述,未报告原始研究样本量、随访时间或效应量等数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic dysfunction-associated steatotic liver disease (MASLD; formerly nonalcoholic fatty liver disease) is an increasingly common cause of chronic liver disease. It is fatty infiltration of the liver with at least one cardiometabolic risk factor, without a secondary cause and no or low alcohol use. People with MASLD and other risk factors (eg, diabetes, obesity) are at higher risk for long-term adverse outcomes, including cirrhosis and hepatocellular carcinoma. Screening for advanced fibrosis involves two-step sequential noninvasive testing. Clinicians should risk stratify using the Fibrosis-4 index. Secondary risk assessment with vibration-controlled transient elastography or ultrasound-based methods is needed in people with indeterminate or high-risk Fibrosis-4 scores. Monitoring and management of earlier stages of the MASLD spectrum in primary care may reduce the risk of adverse outcomes and maximize care before specialist referral. Patients should be counseled on lifestyle interventions (eg, at least 5% weight loss for people with overweight or obesity, healthy diet, at least 150 minutes of moderate aerobic physical activity per week) to improve steatosis and lower cardiovascular risk. Additional lifestyle recommendations include smoking cessation, limited alcohol intake in people with no or mild fibrosis, and no alcohol for those with more significant fibrosis. Semaglutide and resmetirom are approved by the US Food and Drug Administration for treatment of metabolic dysfunction- associated steatohepatitis in patients with moderate or severe fibrosis.

来源:Am Fam Physician,查看原文。版权归原作者所有。

引用

  1. Ohri S, Waterman E, Quiñones AR, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management. Am Fam Physician. 2026. PMID: 42301877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。